Nanoparticle-Based Tolerogenic Vaccines: Next-Generation Strategies for Autoimmune and Allergic Disease Therapies

Abstract

The concurrent rise of autoimmune diseases, which affect nearly 10% of the global population, along with allergic conditions such as asthma, food allergy, and atopic disease, together pose substantial health and economic burdens. Traditional therapies rely on systemic immunosuppression that temporarily mitigates symptoms but often compromises protective immunity, increases infection and malignancy risk, and fails to restore central or peripheral tolerance. These limitations underscore the need for antigen-specific strategies capable of re-establishing durable immune balance. Tolerogenic vaccines have emerged as a promising solution by retraining the immune system to restore antigen-specific tolerance while preserving normal host defense, though challenges remain in efficiently targeting antigen-presenting cells (APCs), avoiding their overactivation, and minimizing off-target effects. Nanoparticles provide a versatile platform to address these hurdles, as their size, composition, and surface modifications can be tailored to direct biodistribution, enhance antigen delivery, and modulate immune signaling. By co-delivering antigens and immunomodulators in programmable ways, nanoparticles offer a pathway to overcome key translational barriers and achieve precise immune reprogramming. This review explores how advances in nanomedicine are being applied to tolerogenic vaccines, focusing on three areas: (1) current nanoparticle platforms, (2) the role of biomaterial selection, and (3) multifunctional engineering strategies, while also considering the clinical outlook and translational challenges of bringing these therapies from bench to bedside.

Introduction

Once considered rare, autoimmune diseases now affect approximately 10% of people worldwide, with the prevalence of these conditions increasing by 42% between 2000 and 2019.[1] Autoimmune diseases are characterized by a breakdown of immunological tolerance, resulting in pathological immune responses against self-antigens. Depending on the specific disorder, tissue damage may be mediated by autoreactive CD4⁺ and CD8⁺ T cells, inflammatory antigen-presenting cells (APCs), immune complexes, or autoantibody-producing B cells. Examples range from systemic pathologies such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), to tissue-specific conditions including type 1 diabetes (T1D), Graves’ disease, and multiple sclerosis (MS). Allergic diseases, by contrast, arise from inappropriate activation of immune pathways normally dedicated to parasitic defense against innocuous environmental antigens (allergens). These responses are typically driven by allergen-specific IgE, Th2 cells, mast cells and basophils, and the prevalence now impacts 10–30% of the global population.

Autoimmune and allergic diseases affect individuals across all demographics; however, they are particularly prevalent in women and children.[2, 3] In addition, their burden is more pronounced in industrialized nations, where changing environmental exposures and hygienic living conditions are hypothesized to skew immune development.[4] The economic implications of these conditions are significant. Autoimmune diseases account for over $100 billion per annum in direct and indirect healthcare costs in the United States,[5] while allergic diseases result in billions of dollars more in emergency care, lost productivity, and long-term pharmaceutical reliance.[6]

Current management strategies for autoimmune and allergic diseases rely on systemic immunosuppression. While effective at symptom mitigation, these therapies can heighten the risk of infection and malignancy, delay wound healing, and adversely affect the kidney, liver, and bone.[7, 8] Thus, there is a critical need for therapies capable of inducing long-term and specific immune tolerance to disease-causing antigens while preserving normal host defense.

Tolerogenic vaccines are a novel therapeutic class that can potentially address this challenge. Unlike traditional vaccines that activate the immune system for disease prevention, tolerogenic vaccines suppress the immune response to specific antigens for disease resolution.[9, 10] To induce antigen-specific tolerance, tolerogenic signals must be delivered in a precise and controlled manner. Emerging approaches use nanoparticles as delivery vehicles to present tolerogenic cues to the cells and tissues responsible for tolerance induction. Because autoimmune and allergic diseases are driven by distinct effector mechanisms, the design of tolerogenic nanoparticle strategies must be tailored to the underlying immunopathology. In allergic disease, pathology is dominated by Th2-skewed immunity and IgE-mediated activation of mast cells and basophils; thus, effective interventions often aim to suppress IgE class switching, reprogram Th2 cells, or induce allergen-specific IL-10–producing regulatory T cells (Tregs).[11, 12] In contrast, many autoimmune diseases (such as MS, RA, and T1D) are driven by autoreactive CD4⁺ and CD8⁺ T cells, inflammatory APCs, and pathogenic autoantibody production.[13-15] In such cases, nanoparticle design may prioritize targeting dendritic cells, macrophages, or autoreactive antigen-specific T cell and B cell subsets to induce deletion, anergy, or regulatory differentiation. Consequently, optimal antigen format, delivery route, and immunomodulatory cues differ across disease classes, and disease-specific mechanistic understanding must guide nanoparticle engineering for antigen-specific tolerance. In this review, we examine the key design principles of nanoparticles used in tolerogenic vaccines and highlight next-generation engineering strategies aimed at realizing their potential in treating autoimmune and allergic disease.

Download the full article as PDF here Nanoparticle-Based Tolerogenic Vaccines

or continue reading here

Nanoparticle-Based Tolerogenic Vaccines: Next-Generation Strategies for Autoimmune and Allergic Disease Therapies, Benjamin E. Nachod, Ajay S. Thatte, Rohan Palanki, Michael J. Mitchell, First published: 26 December 2025 https://doi.org/10.1002/anie.202524097

Read more on World Immunization Week here: